ArticleJACC. Cardiovascular interventions2015
Percutaneous Left Atrial Appendage Closure With the Watchman Device: Long-Term Results Up to 5 Years.
Article in JACC. Cardiovascular interventions, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Short-term antiplatelet versus anticoagulant therapy after left atrial appendage closure: a systematic review and meta-analysis.Journal of thrombosis and thrombolysis · 2024Pooled it
- Short-Term Antiplatelet Versus Anticoagulant Therapy After Left Atrial Appendage Occlusion: A Systematic Review and Meta-Analysis.JACC. Clinical electrophysiology · 2020Pooled it
- Variations in the Medical Device Authorization and Reimbursement Landscape: A Case Study of 2 Cardiovascular Devices Across 4 Countries.Circulation. Cardiovascular quality and outcomes · 2025Article
- Long-term outcomes of successful left atrial appendage occlusion with focus on stroke prevention: 10-year follow-up of a single-center registry.Heart rhythm O2 · 2023Article
- Short-term antithrombotic strategies after left atrial appendage occlusion: a systematic review and network meta-analysis.Frontiers in pharmacology · 2023Review
- Changes in fibrinolytic activity and coagulation factors after epicardial left atrial appendage closure in patients with atrial fibrillation.Journal of thoracic disease · 2022Article
- Left atrial appendage occlusion in a mirror-image dextrocardia: A case report and review of literature.World journal of clinical cases · 2022Article
- Impact of sex differences on outcomes in patients with non-valvular atrial fibrillation undergoing left atrial appendage closure: A single-center experience.International journal of medical sciences · 2021Article
- Review
- Percutaneous retrieval of an embolized left atrial appendage closure device from the left atrium in a patient with previous MitraClips.BMC cardiovascular disorders · 2019Article
- Long term outcomes after left atrial appendage closure with the LARIAT device-Stroke risk reduction over five years follow-up.PloS one · 2018Observational
- The "absent" left atrial appendage….HeartRhythm case reports · 2017Article
- Five years of keeping a watch on the left atrial appendage-how has the WATCHMAN fared?Journal of thoracic disease · 2016Article
- Left atrial appendage exclusion for atrial fibrillation: does the protection from stroke prevail in the long-term?Journal of thoracic disease · 2016Article
- Percutaneous left atrial appendage closure: here to stay.Journal of thoracic disease · 2016Article
- Percutaneous Left Atrial Appendage Closure: is there a Role in Valvular Atrial Fibrillation.Journal of atrial fibrillationReview
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe aim of this study was to evaluate long-term outcomes in patients with atrial fibrillation undergoing percutaneous left atrial appendage (LAA) closure with the Watchman device.
backgroundAtrial fibrillation is one of the most common arrhythmias and is associated with a high risk for cardioembolic ischemic events, most notably stroke. Percutaneous LAA closure is an alternative to oral anticoagulation, because most thrombi originate from the LAA.
methodsAll consecutive patients with minimum CHADS2 or CHA2DS2-VASc scores of 1 who underwent LAA closure with the Watchman device between June 2006 and August 2010 were eligible. Follow-up examinations were performed after 45 days to 3 months, 6 months, and 1 year and thereafter annually. Afterward, alternating office visits and telephone follow-up were performed every 6 months.
resultsA total of 102 patients were included. The mean age was 71.6 ± 8.8 years, and 37.3% were women. The mean CHADS2 and CHA2DS2-VASc scores were 2.7 ± 1.3 and 4.3 ± 1.7, respectively. Procedural success was achieved in 96.1% of patients. During a mean follow-up period of 3.0 ± 1.6 years, the annual rates of transient ischemic attack, stroke, intracranial hemorrhage, and death were 0.7%, 0.7%, 1.1%, and 3.5%, respectively.
conclusionsLAA closure with the Watchman device is safe and feasible for stroke protection in patients with atrial fibrillation. Low ischemic events rates demonstrate its effectiveness during long-term follow-up.
Indexed as
Identifiers
26738659What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.